Olfactory Hallucinations as a Unique Presentation of Anti-Depressant Discontinuation Syndrome by Varade, Shweta, MD et al.
Lehigh Valley Health Network
LVHN Scholarly Works
Department of Medicine
Olfactory Hallucinations as a Unique Presentation
of Anti-Depressant Discontinuation Syndrome
Shweta Varade MD
Lehigh Valley Health Network, Shweta.Varade@lvhn.org
Casey Judge DO
Lehigh Valley Health Network, Casey.Judge@lvhn.org
Megan Leary MD
Lehigh Valley Health Network, Megan_C.Leary@lvhn.org
Preet Varade MD
Lehigh Valley Health Network, Preet_M.Varade@lvhn.org
Follow this and additional works at: https://scholarlyworks.lvhn.org/medicine
Part of the Neurology Commons
This Poster is brought to you for free and open access by LVHN Scholarly Works. It has been accepted for inclusion in LVHN Scholarly Works by an
authorized administrator. For more information, please contact LibraryServices@lvhn.org.
Published In/Presented At
Varade, S. Judge, C. Leary, M. Varade, P. (2019, May 7). Olfactory Hallucinations as a Unique Presentation of Anti-Depressant
Discontinuation Syndrome. Poster Presented at: The American Academy of Neurology (AAN) Annual Meeting, Philadelphia, PA.
LVHN.org
© 2019 Lehigh Valley Health Network
 Olfactory Hallucinations as a Unique Presentation of Anti-Depressant Discontinuation Syndrome 
Shweta Varade, MD, Casey Judge, DO, Megan Leary, MD, Preet Varade, MD
Lehigh Valley Health Network, Allentown, Pa.
INTRODUCTION: 
Discontinuation syndromes have been reported following 
abrupt cessation of anti-depressants that include Selective 
Serotonin Reuptake Inhibitors (SSRIs) and Tricyclic Anti-
depressants (TCAs). Commonly reported symptoms include 
insomnia, nausea, imbalance, sensory disturbance, and 
hyperarousal. Less frequently, shock-like sensation, delirium, 
and mania have also been documented. Visual and auditory 
hallucinations are even rarer and have thus far been 
described in only one case report. Olfactory hallucinations, 
however, have not been reported as a manifestation of 
discontinuation syndrome to the best of our knowledge. 
 
CASE PRESENTATION: 
A 49 year old woman with a past medical history of Diabetes 
Mellitus Type II, coronary artery disease, hypertension, 
hyperlipidemia, and tobacco abuse presented with complaints 
of dizziness, episodes of transient alterations in 
consciousness, and “horrific smells” of mold and fire. Initial 
neurological examination was normal with the exception of 
decreased attention, concentration, and memory. 
Computerized Tomography (CT) of the head was negative for 
acute findings. She was offered admission for further workup 
but declined, however, returned the following day with the 
same complaints as well as amnesia and confusion. Her 
neurological exam remained unchanged. Further workup 
included Magnetic Resonance Imaging (MRI) of the brain 
which was negative for any structural abnormalities, 
prolonged electroencephalogram (EEG) which did not reveal 
any evidence of epileptiform discharges, and cerebrospinal 
fluid analysis that was unremarkable.
After discussing the risks and benefits, she was discharged 
home on anti-convulsants due to concern for seizures, 
despite a negative EEG. She returned to the emergency 
department the following day again with recurrence of 
symptoms. Further history revealed that the patient had 
abruptly discontinued paroxetine two weeks prior to 
presentation. The anti-convulsant was discontinued and she 
was restarted on paroxetine and discharged home. At a follow 
up visit with her primary care three days later, she reported 
cessation of any olfactory hallucinations. 
 
DISCUSSION:  
Discontinuation syndromes can occur with any SSRI but is 
more frequently noted with Paroxetine2. The syndrome can 
occur after treatment duration of as little as two months and 
tapering off of the medications has not shown to eliminate the 
risk of withdrawal symptoms2, which can last as long as a few 
days to several weeks.2 
There is a known link between depression and the perception 
of non-existent odors (phantosmia/parosmias or olfactory 
hallucinations), that are typically described as “unpleasant.”1 
Abnormal functioning in the orbitofrontal cortex4  has been 
thought to affect olfactory processes in depressive disorders, 
possibly due to anatomical proximity. In many cases, these 
symptoms can be treated with anti-depressants.1 
It has been hypothesized that hallucinations as a 
discontinuation syndrome may be a result of the decrease  
in the available synaptic serotonin from downregulated 
serotonin receptors or due to secondary effects on other 
neurotransmitters.2 
Sensory neurons release glutamate to activate post-synaptic 
targets in the olfactory pathway.4 This is modulated by the 
GABA-B receptor which works to reduce neurotransmitter 
release in olfactory neurons.4 Serotonin activates 
periglomerular neurons leading to an increase in GABA-B 
activity and thereby turning down the strength of odor input  
to the brain.4 Thus patients who may be pre-disposed to 
phantosmia/parosmia may have a dampened sense of 
awareness of smell while they are being treated with  
anti-depressants such as paroxetine. 
Conversely, there is a decreased level of GABA in the 
cingulate gyrus, right and left insula, and left amygdala in 
patients with depression.5 A study in rhesus monkeys3 
determined a direct anterior retrograde pathway from the 
anterior cingulate gyrus to the primary olfactory cortex, which 
may activate the entire olfactory cortex to mediate the 
process of rapid attention to olfactory stimulus.3 This suggests 
that in patients with decreased GABA activity, such as when  
anti-depressants are suddenly discontinued, it may be  
possible for them to experience a heightened awareness of 
phantosmias or parosmias. 
 
CONCLUSION: 
While anti-depressant discontinuation syndromes have been 
previously reported, there is little available data on the 
phenomenon of olfactory hallucinations as a symptom. In part, 
this may be due to the fact that parosmias/phantosmias are 
rarely reported spontaneously by patients and often not 
explicitly asked about by clinicians.2 We present a unique case 
of a patient who experienced olfactory hallucinations shortly 
after discontinuing paroxetine.
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Image 1 (left):  Anatomical representation of olfactory system
Image 3: Effects of serotonin on the olfactory pathway
Image 2 (right): Structures involved in the processing of olfactory 
information. Olfactory information is carried to the primary olfactory cortex 
(olfactory nucleus, piriform cortex, olfactory tubercle, amygdaloid complex, 
and enterorhinal cortex) and then projected to the thalamus, orbitofrontal 
cortex, insula cortex, and hippocampus.
